Merck & Co. Inc. has announced promising results from the Phase 1 KANDLELIT-001 study, which evaluated MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer and non-small cell lung cancer harboring KRAS G12C mutations. The study demonstrated a manageable safety profile and encouraging antitumor activity for MK-1084, both as a monotherapy and in combination with other treatments. In non-small cell lung cancer, MK-1084 in combination with KEYTRUDA showed an objective response rate $(ORR.AU)$ of 77% in untreated metastatic patients with PD-L1 expression, while as a monotherapy, it achieved an ORR of 38% in previously treated patients. The findings suggest significant potential for MK-1084 in addressing prevalent KRAS mutations in cancer, representing a promising advancement in Merck's oncology pipeline.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。